Valuation DexCom, Inc. BOERSE MUENCHEN
Stocks
DC4
US2521311074
Medical Equipment, Supplies & Distribution
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.09 EUR | -0.19% |
|
-6.49% | +10.55% |
| 06-16 | AI Can Play 'Significant' Role in Tech for Managing Diabetes, Says David Roman | MT |
| 06-15 | Piper Sandler Adjusts Price Target on DexCom to $88 From $75, Maintains Overweight Rating | MT |
Company Valuation: DexCom, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 52,042 | 43,740 | 47,945 | 30,377 | 25,885 | 28,230 | - | - |
| Change | - | -15.95% | 9.61% | -36.64% | -14.79% | 9.06% | - | - |
| Enterprise Value (EV) 1 | 52,692 | 45,068 | 49,813 | 31,073 | 26,209 | 27,861 | 26,983 | 25,877 |
| Change | - | -14.47% | 10.53% | -37.62% | -15.65% | 6.3% | -3.15% | -4.1% |
| P/E | 346x | 138x | 95.5x | 54.8x | 31.8x | 29.9x | 25x | 20.8x |
| PBR | 23.1x | 20.5x | 23.1x | 15.1x | 9.3x | 10.9x | 10.5x | 7.62x |
| PEG | - | 1x | 1.6x | 5.94x | 0.7x | 1.7x | 1.3x | 1x |
| Capitalization / Revenue | 21.3x | 15x | 13.2x | 7.53x | 5.55x | 5.4x | 4.84x | 4.33x |
| EV / Revenue | 21.5x | 15.5x | 13.8x | 7.7x | 5.62x | 5.33x | 4.63x | 3.97x |
| EV / EBITDA | 111x | 60x | 49.1x | 28.1x | 19.4x | 17x | 14.1x | 11.6x |
| EV / EBIT | 142x | 92.9x | 69.3x | 41x | 27x | 23x | 18.8x | 15x |
| EV / FCF | 989x | 148x | 97.3x | 49.3x | 24.3x | 28x | 21.7x | 17.1x |
| FCF Yield | 0.1% | 0.68% | 1.03% | 2.03% | 4.11% | 3.57% | 4.61% | 5.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.3875 | 0.82 | 1.3 | 1.42 | 2.09 | 2.448 | 2.921 | 3.51 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,448 | 2,910 | 3,622 | 4,033 | 4,662 | 5,225 | 5,830 | 6,525 |
| EBITDA 1 | 472.7 | 751.6 | 1,014 | 1,105 | 1,349 | 1,639 | 1,914 | 2,227 |
| EBIT 1 | 370.7 | 485.1 | 718.6 | 757.1 | 969.3 | 1,212 | 1,438 | 1,723 |
| Net income 1 | 154.7 | 341.2 | 541.5 | 576.2 | 836.3 | 962.6 | 1,158 | 1,378 |
| Net Debt 1 | 650.1 | 1,328 | 1,868 | 695.9 | 323.2 | -369.5 | -1,248 | -2,354 |
| Reference price 2 | 134.24 | 113.24 | 124.09 | 77.77 | 66.37 | 73.16 | 73.16 | 73.16 |
| Nbr of stocks (in thousands) | 387,688 | 386,258 | 386,374 | 390,595 | 390,016 | 385,873 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/13/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.79x | 3.37x | 12.67x | 2.81% | 158B | |
| 20.44x | 3.52x | 12.66x | 3.52% | 104B | |
| 34.24x | 8.33x | 21.84x | 1.17% | 56.43B | |
| 14.83x | 0.18x | 11.12x | 0.84% | 54.76B | |
| 36.17x | 2.91x | 10x | 2.65% | 40B | |
| 35.51x | 1.31x | 11.57x | 0.22% | 31.36B | |
| 39.14x | 6.77x | 24.42x | 0.27% | 23.28B | |
| 23.94x | 3.05x | 12.47x | 1.35% | 20.41B | |
| 22.91x | 3.3x | 11.87x | 1.28% | 20.13B | |
| Average | 27.77x | 3.64x | 14.29x | 1.57% | 56.51B | |
| Weighted average by Cap. | 25.36x | 3.59x | 13.74x | 2.15% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXCM Stock
- DC4 Stock
- Valuation DexCom, Inc.
Select your edition
All financial news and data tailored to specific country editions
